Advertisement

Psychopharmaka

  • Martin J. Lohse
  • Anna Lorenzen
  • Bruno Müller-Oerlinghausen

Zusammenfassung

Die Verordnungsstruktur der Psychopharmaka hat sich in den letzten 10 Jahren auffällig verändert. Die Verordnungen der früher führenden Tranquillantien sind 2003 weiter rückläufig. Umgekehrt haben sich die Anti-depressivaverordnungen seit 1994 mehr als verdoppelt. Dieser Trend setzte sich 2003 durch die Anstiege bei den selektiv wirkenden Antidepressiva fort (+22%), Demgegenüber haben sich Neuroleptika auf fast konstantem Niveau gehalten. Allerdings haben sich die Verordnungen atypischer Neuroleptika mit geringerer Störung der Motorik weiter kräftig erhöht (+20%), während klassische hochpotente Neuroleptika weniger eingesetzt wurden (−5%). Pflanzliche Psychopharmaka sind erneut rückläufig (−12%).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abraham J (2003): The science and politics of medicines control. Drug Saf 26: 135–143.PubMedCrossRefGoogle Scholar
  2. Anonym (2003): Lithium-Therapie bei der manisch-depressiven Erkrankung: Immer noch der Standard? Arzneimittelbrief 37:49–51.Google Scholar
  3. Apter JT, Allen LA (1999): Buspirone: future directions. J Clin Psychopharmacol 19: 86–93.PubMedCrossRefGoogle Scholar
  4. Arzneimittelkommission der deutschen Apotheker (2002): BfArM-Bescheid zu Kava-Kava. Pharm Ztg 147:6–7.Google Scholar
  5. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (1997): Empfehlungen zur Therapie der Depression. 1. Aufl. Sonderheft Arzneiverordnung in der Praxis. September 1997.Google Scholar
  6. Arzneimittelkommission der deutschen Ärzteschaft (Hrsg) (2003): Empfehlungen zur Therapie von Angst-und Zwangsstörungen. 2. Aufl. Sonderheft Arzneiverordnung in der Praxis.Google Scholar
  7. Arzneimittelkommission der deutschen Ärzteschaft (2001): Hepatotoxizität des neuen Antidepressivums Nefazodon (Nefadar?). Dtsch Ärztebl 98: B52.Google Scholar
  8. Baptista T, Lacruz A, Angeles F, Silvera R, de Mendoza S, Mendoza MT et al (2001): Endocrine and metabolic abnormalities involved in obesity associated with typical antipsychotic drug administration. Pharmacopsychiatry 34: 223–231.PubMedCrossRefGoogle Scholar
  9. Barbenel DM, Yusufi B, O’Shea D, Bench CJ (2000): Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol 14: 84–86.PubMedCrossRefGoogle Scholar
  10. Barbui C, Hotopf M (2001): Amitriptyline vs. the rest: still the leading antidepressant after 40 years of randomised controlled trials. Brit J Psychiatry 178:129–144.CrossRefGoogle Scholar
  11. Barbui C, Hotopf M, Freemantle N, Boynton J, Churchill R, Eccles MP et al (2000): Selective serotonin reuptake inhibitors versus tricyclic and heterocyclic antidepressants: comparison of drug adherence. Cochrane Database Syst Rev 2000(4): CD002791.Google Scholar
  12. Bauer M, Dopfner S (1999): Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19: 427–434.PubMedCrossRefGoogle Scholar
  13. Bauer M, Whybrow PC, Angst C, Verslani M, Möller H-J (2002): World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for biological treatment of unipolar depressive disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5–43.PubMedCrossRefGoogle Scholar
  14. Baumann P (1996): Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 31:444–469.PubMedCrossRefGoogle Scholar
  15. Benkert O, Szegedi A, Kohnen R (2000): Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 61: 656–663.PubMedCrossRefGoogle Scholar
  16. Berlin I, Lecrubier Y (1996): Food and drug interactions with monoamine oxidase inhibitors: How safe are the newer agents? CNS Drugs 5:403–413.CrossRefGoogle Scholar
  17. Berner MM, Riemann D, Berger M (2002): The efficacy of hypericum extracts with more than 1% or less than 0.5% hyperforin content compared to placebo in the treatment of major depression — a systematic review and analysis of randomized controlled trials. Eur Arch Psychiatry Clin Neurosci 252(suppl 1): P230 (Abstract).Google Scholar
  18. Birmes P, Coppin D, Schmitt L, Lauque D (2003): Serotonin syndrome: a brief review. CMAJ 168:1439–1442.PubMedGoogle Scholar
  19. Bon S, Hartmann K, Kuhn M (1999): Johanniskraut: Ein Enzyminduktor? Schweiz Ap Ztg 16: 535–536.Google Scholar
  20. Braun M, Strasser RH (1997): Trizyklische Antidepressiva und kongestive Kardio-mypathie. Internist 38:1236–1238.PubMedGoogle Scholar
  21. Caley CF, Weber SS (1995): Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Ann Pharmacother 29:152–160.PubMedGoogle Scholar
  22. Carriere P, Bonhomme D, Lemperiere T (2000): Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 15: 321–329.PubMedCrossRefGoogle Scholar
  23. Carter CS, Mulsant BH, Sweet RA, Maxwell RA, Coley K et al (1995): Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications. Psychopharmacol Bull 31: 719–25.PubMedGoogle Scholar
  24. Carvajal GP, Garcia D, Sanchez SA, Velasco MA, Rueda D, Lucena ML (2002): Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry 63: 135–137.CrossRefGoogle Scholar
  25. Chick J, Howlett H, Morgan MY, Ritson B (2000): United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol 35: 176–187.PubMedGoogle Scholar
  26. Chouinard G, Jones B, Remington G, Bloom D, Addington D et al (1993): A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13: 25–40.PubMedCrossRefGoogle Scholar
  27. Colonna L, Saleem P, Dondey-Nouvel L, Rein W (2000): Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 15:13–22.CrossRefGoogle Scholar
  28. Correll CU, Leucht S, Kane JM (2004): Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 161:414–425.PubMedCrossRefGoogle Scholar
  29. Csernansky JG, Mahmoud R, Brenner R (2002): A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 346: 16–22.PubMedCrossRefGoogle Scholar
  30. Dardennes R, Even C, Bange F, Heim A (1995): Comparison of carbamazepine and lithium in the prophylaxis of bipolar disorders — a metaanalysis. Brit J Psychiat 166:378–381.PubMedCrossRefGoogle Scholar
  31. Davis JM, Chen N, Glick ID (2003): A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553–564.PubMedCrossRefGoogle Scholar
  32. De Abajo FJ, Rodriguez LAG, Montero D (1999): Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. Brit Med J 319:1106–1109.PubMedCrossRefGoogle Scholar
  33. De Smet PAGM, Touw DJ (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355:575–576.PubMedCrossRefGoogle Scholar
  34. Dettling M, Hellweg R, Cascorbi I, Deichle U, Weise L, Müller-Oerlinghausen B (1999): Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine? Pharmacopsychiatry 32:32:110–112.PubMedCrossRefGoogle Scholar
  35. Di Carlo G, Borreli F, Ernst E, Izzo AA (2001): St John’s wort: Prozac from the plant kingdom. Trends Pharmacol Sci 22: 292–297.PubMedCrossRefGoogle Scholar
  36. Dinan TG (2002): Lithium in bipolar mood disorder. Evidence suggests that lithium should still be first choice for prophylactic treatment. Brit Med J 324: 988–989.CrossRefGoogle Scholar
  37. Donovan S, Clayton A, Beeharry M, Jones S, Kirk C, Waters K et al (2000): Deliberate self-harm and antidepressant drugs. Investigation of a possible link. Br J Psychiatry 177:551–556.PubMedCrossRefGoogle Scholar
  38. Dose M (2003): Was ist der Stellenwert atypischer Neuroleptika für die Praxis? Arzneiverordnung in der Praxis 30, Heft 3: 5–6.Google Scholar
  39. Duggan L, Fenton M, Dardennes RM, El-Dosoky A, Indran S (2000): Olanzapine for schizophrenia. Cochrane Database Syst Rev 2: CD001359.Google Scholar
  40. Einarson TR, Arikian SR, Casciano J, Doyle JJ (1999): Comparison of extended-release venlafaxine, selective serotonin reuptake inhibitors, and tricyclic anti-depressants in the treatment of depression: a meta-analysis of randomized controlled trials. Clin Ther 21: 296–308.PubMedCrossRefGoogle Scholar
  41. Elliger T, Englert E, Freisleder FJ, Friedrich M, Gierow B et al (1994): Zur Behandlung schizophrener Psychosen des Kindes-und Jugendalters mit Clozapin (Leponex). Konsensuskonferenz vom 4. März 1994, Kinder und Jugendpsychiatrie. Z Kinder-Jugendpsychiat 22:325–327.Google Scholar
  42. Elliger TJ, Trott GE, Nissen G (1990): Prevalence of psychotropic medication in childhood and adolescence in the Federal Republic of Germany. Pharmacopsychiatry 23: 38–44.PubMedCrossRefGoogle Scholar
  43. Ener RA, Meglathery SB, van Decker WA, Gallagher RM (2003) Serotonin syndrome and other serotonergic disorders. Pain Medicine 4:63–74.PubMedCrossRefGoogle Scholar
  44. Ernst E (2000): Second thoughts about safety of St. John’s wort. Lancet 354: 2014–2016.CrossRefGoogle Scholar
  45. Ferguson JM, Wesnes KA, Schwartz GE (2003) Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. Int Clin Psychopharmacol 18:9–14.PubMedCrossRefGoogle Scholar
  46. Franchini L, Zanardi R, Gasperini M, Perez J, Smeraldi E (1996): Fluvoxamine and lithium in long-term treatment of unipolar subjects with high recurrence rate. J Affect Disord 38:67–69.PubMedCrossRefGoogle Scholar
  47. Frank E, Kupfer DJ, Perel JM (1990): Three-years outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093–1099.PubMedCrossRefGoogle Scholar
  48. Gale C, Oakley-Browne M (2000) Anxiety disorder. Brit Med J 321:1204–1207.PubMedCrossRefGoogle Scholar
  49. Geddes J, Freemantle N, Harrison P et al (2000): Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. Brit Med J 321:1371–1376.PubMedCrossRefGoogle Scholar
  50. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J (2001): SSRIs versus other antidepressants for depressive disorder. Update Software Ltd Oxford, The Cochrane Library — Issue 1.Google Scholar
  51. Geiselmann B, Linden M (1991): Prescription and intake patterns in long-term and ultra-long-term benzodiazepine treatment in primary care practice. Pharmacopsychiatry 24: 55–61.PubMedCrossRefGoogle Scholar
  52. Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E (2000): Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA 283: 3082–3088.PubMedCrossRefGoogle Scholar
  53. Goodnick PJ, Barrios CA (2001): Use of olanzapine in non-psychotic psychiatric disorders. Expert Opin Pharmacother 2:667–680.PubMedCrossRefGoogle Scholar
  54. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D (2003): Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290:1467–1473.PubMedCrossRefGoogle Scholar
  55. Goodwin GM, Bowden CL, Calabrese JR, Grunze H, Kasper S et al (2004): A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 65: 432–441.PubMedCrossRefGoogle Scholar
  56. Greil W, Ludwig-Mayerhofer W, Erazo N, Engel RR, Czernik A et al (1996): Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: a randomised study. J Affect Disord 40:179–190.PubMedCrossRefGoogle Scholar
  57. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S (2001): Mirtazapine versus venlafaxine in hospitalized severely depressed patients with melancholic features. J Clin Psychopharmacol 21:425–431.PubMedCrossRefGoogle Scholar
  58. Guzelcan Y, Scholte WF, Assies J, Becker HE (2001): Mania during the use of a combination preparation with St. John’s wort (Hypericum perforatum). Ned Tijdschr Geneeskd 6:1943–1945.Google Scholar
  59. Healy D (2003): Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother Psychosom 72: 71–79.PubMedCrossRefGoogle Scholar
  60. Hypericum Depression Trial Study Group (2002): Effect of Hypericum perforatum (St John’s Wort) in major depressive disorder. JAMA 287:1807–1814.CrossRefGoogle Scholar
  61. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I (1999): Pharmacokinetic interaction of digoxin with an herbal extract from St. John’s wort (Hypericum perforatum). Clin Pharmacol Ther 66: 338–345.PubMedCrossRefGoogle Scholar
  62. Johne A, Schmider J, Brockmöller J, Stadelmann AM, Stormer E, Bauer S et al (2002): Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum). J Clin Psychopharmacol 22: 46–54.PubMedCrossRefGoogle Scholar
  63. Jureidini JN, Doecke CJ, Mansfield PR, Haby MM, Menkes DB, Tonkin AL (2004): Efficacy and safety of antidepressants for children and adolescents. BMJ 328: 879–883.PubMedCrossRefGoogle Scholar
  64. Kane J, Honigfeld G, Singer J, Meltzer H (1988): Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789–796.PubMedCrossRefGoogle Scholar
  65. Kane JM, Eerdekens M, Lindenmayer JP, Keith S J, Lesem M, Karcher K (2003): Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 160:1125–1132.PubMedCrossRefGoogle Scholar
  66. Kappler J, Menges C, Ferbert A, Ebel H (1994): Schwere „Spät“ dystonie nach „Neuroleptanxiolyse“ mit Fluspirilen. Nervenarzt 65:66–68.PubMedGoogle Scholar
  67. Kasper S (1996): Mirtazapin. Klinisches Profil eines noradrenalin-und serotonin-spezifischen Antidepressivums. Arzneimitteltherapie 14(9): 257–259.Google Scholar
  68. Kimko HC, Cross JT, Abernethy DR (1999): Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmakokinet 37:457–470.CrossRefGoogle Scholar
  69. Knopf H, Melchert H-U (2003): Bundes-Gesundheitssurvey: Arzneimittelgebrauch. Robert-Koch-Institut Berlin (Hrsg).Google Scholar
  70. Kornhuber J (1994): Potentielle Antipsychotica mit neuartigen Wirkmechanismen. In: Riederer P, Laux G, Pöldinger W (Hrsg): Neuropsychopharmaka, Bd. 4: Neuroleptica. Springer-Verlag, Wien New York, S. 185–196.Google Scholar
  71. Laakmann G, Schüle C, Baghai T, Kieser M (1998): St. John’s wort in mild to moderate depression: The relevance of hyperforin for clinical efficacy. Pharmacopsychiatry 31(Suppl): 54–59.PubMedCrossRefGoogle Scholar
  72. Lapierre YD (1989): A review of trimipramine 30 years of clinical use. Drugs 38(suppl 1): 17–24.PubMedCrossRefGoogle Scholar
  73. Laties AM (2002): Quetiapine and cataracts. Am J Psychiatry 159: 322–323.PubMedCrossRefGoogle Scholar
  74. Laux G, Volz H-P, Möller H-J (1995): Newer and older monoamine oxidase inhibitors. CNS Drugs 3:145–158.CrossRefGoogle Scholar
  75. Lantz MS, Buchalter E, Giambanco V (1999): St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 12: 7–10.PubMedCrossRefGoogle Scholar
  76. Lehmann K, Müller-Oerlinghausen B (1993): Kosten-/Nutzen-Kalkulation der Lithium-Langzeit-Prophylaxe. Klin Pharmakol Aktuell 4:68–70.Google Scholar
  77. Lepine JP, Gastpar M, Mendlewicz J, Tylee A (1997): Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 12:19–29.PubMedCrossRefGoogle Scholar
  78. Lesch OM, Riegler A, Gutierrez K, Hertling I, Ramskogler K, Semler B et al (2001): The European acamprosate trials. Conclusions for research and therapy. J Biomed Sci 8:89–95.PubMedCrossRefGoogle Scholar
  79. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM (2003a): Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 160:1209–1222.PubMedCrossRefGoogle Scholar
  80. Leucht S, Wahlbeck K, Hamann J, Kissling W (2003b): New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361:1581–1589.PubMedCrossRefGoogle Scholar
  81. Linde K, Mulrow CD (2000): St. John’s wort for depression. Cochrane Database Syst Rev 2000(2):CD000448.Google Scholar
  82. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996): St John’s wort for depression — an overview and meta-analysis of randomised clinical trials. Brit Med J 313: 253–258.PubMedCrossRefGoogle Scholar
  83. Linden M, Gothe H (1993): Benzodiazepine substitution in medical practice. Analysis of pharmacoepidemiological data based on expert interviews. Pharmacopsychiatry 26:107–113.PubMedCrossRefGoogle Scholar
  84. MacGillivray S, Arroll B, Hatcher S, Ogston S, Reid I, Sullivan F et al (2003): Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. Brit Med J 326:1014–1019.PubMedCrossRefGoogle Scholar
  85. Macritchie KAN, Geddes MR, Scott J, Haslam DRS, Goodwin GM (2001): Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorders. Cochrane Review. In: The Cochrane Library Issue 3. Oxford, Updated Software.Google Scholar
  86. Marder SR, Meibach RC (1994): Risperidone in the treatment of schizophrenia. Am J Psychiatry 151: 825–835.PubMedGoogle Scholar
  87. Melkersson K, Dahl ML (2004): Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs 64: 701–723.PubMedCrossRefGoogle Scholar
  88. Möller H-J (1999): Atypical neuroleptics: a new approach in the treatment of negative symptoms. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 99–107.PubMedCrossRefGoogle Scholar
  89. Möller H-J, Volz HP, Reimann IW, Stoll KD (2001): Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group. J Clin Psychopharmacol 21: 59–65.PubMedCrossRefGoogle Scholar
  90. Moncrieff J (2001): Are antidepressants overrated? A review of methodological problems in antidepressant trials. J Nerv Ment Dis 189:288–295.PubMedCrossRefGoogle Scholar
  91. Montgomery SA, Roberts A, Patel AG (1994): Placebo-controlled efficacy of antidepressants in continuation treatment. Int Clin Psychopharmacology 9:49–53.CrossRefGoogle Scholar
  92. Montgomery S, Ferguson JM, Schwartz GE (2003): The antidepressant efficacy of reboxetine in patients with severe depression. J Clin Psychopharmacol 23:45–50.PubMedCrossRefGoogle Scholar
  93. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM et al (2000): St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500–7502.PubMedCrossRefGoogle Scholar
  94. Moses EL, Mallinger AG (2000): St. John’s wort: three cases of possible mania induction. J Clin Psychopharmacol 20:115–117.PubMedCrossRefGoogle Scholar
  95. MTA Cooperative Group (1999): A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiat 56: 1073–1086.CrossRefGoogle Scholar
  96. Müller-Oerlinghausen B (2001): Abhängigkeit und Mißbrauch von Substanzen. Dtsch Ärztebl 98: A1625–A1627.Google Scholar
  97. Müller-Oerlinghausen B, Berghöfer A (1999): Antidepressants and suicidal risk. J Clin Psychiatry 60(suppl 2): S94–S99.Google Scholar
  98. Müller-Oerlinghausen B, Berghöfer A, Ahrens B (2003): The antisuicidal and mortality-reducing effect of lithium prophylaxis: consequences for guidelines in clinical psychiatry. Can J Psychiatry 48:433–439.PubMedGoogle Scholar
  99. Müller-Oerlinghausen B, Berghöfer A, Bauer M (2002): Bipolar disorder. Lancet 359: 241–247.PubMedCrossRefGoogle Scholar
  100. Müller-Oerlinghausen B, Greil W, Berghöfer A (Hrsg) (1997): Die Lithiumtherapie. Nutzen Risiken Alternativen. Springer-Verlag, Berlin Heidelberg New York.Google Scholar
  101. Nierenberg AA, Burt T, Matthews J, Weiss AP (1999): Mania associated with St. John’s wort. Biol Psychiatry 46: 1707–1708.CrossRefGoogle Scholar
  102. Oeljeschläger B, Müller-Oerlinghausen B (2004): Wege zur Optimierung der individuellen antidepressiven Therapie. Deutsches Ärzteblatt 101: A 1337–1340.Google Scholar
  103. Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA (1998): Anti-depressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 55: 310–316.PubMedCrossRefGoogle Scholar
  104. Parker V, Wong AH, Boon HS, Seeman MV (2001): Adverse reactions to St John’s wort. Can J Psychiatry 46: 77–79.PubMedGoogle Scholar
  105. Philipp M, Kohnen R, Hiller KO (1999): Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks. Brit Med J 319:1534–1538.PubMedCrossRefGoogle Scholar
  106. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J (2000): Indinavir concentrations and St John’s wort. Lancet 355: 547–548.PubMedCrossRefGoogle Scholar
  107. Rickels K, Rynn M (2002): Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63(Suppl 14): 9–16.PubMedGoogle Scholar
  108. Riederer P, Laux G, Pöldinger W (Hrsg) (1993): Neuropsychopharmaka Bd. 3 Antidepressiva und Phasenprophylaktika. Springer-Verlag, Wien New York.Google Scholar
  109. Rüther E, Degner D, Munzel U, Brunner E, Lenhard G, Biehl J, Vogtle-Junkert U (1999): Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry 32:127–135.PubMedCrossRefGoogle Scholar
  110. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G (2000): Acute heart transplant rejection due to Saint John’s wort. Lancet 355: 548–549.PubMedCrossRefGoogle Scholar
  111. Safer DJ (2000): Are stimulants overprescribed for youths with ADHD? Ann Clin Psychiatry 12: 55–62.PubMedGoogle Scholar
  112. Sass H, Soyka M, Mann K, Zieglgansberger W (1996): Relapse prevention by acam-prosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry 53:673–680.PubMedCrossRefGoogle Scholar
  113. ’schizophrenia and Diabetes 2003’ Expert Consensus Meeting, Dublin, 3–4 October 2003: consensus summary. Br J Psychiatry 184(suppl 47): s112–s114.Google Scholar
  114. Schnyder U, Koller-Leiser A (1996): A double-blind, multicentre study of paroxetine and maprotiline in major depression. Can J Psychiatry 41: 239–244.PubMedGoogle Scholar
  115. Schou M (1998): Has the time come to abandon prophylactic lithium treatment? A review for clinicians. Pharmacopsychiatry 31: 210–215.PubMedCrossRefGoogle Scholar
  116. Schrader E (2000): Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psycho-pharmacol 15: 61–68.CrossRefGoogle Scholar
  117. Schulz V, Hänsel R (Hrsg) (1996): Rationale Phytotherapie. Ratgeber für die ärztliche Praxis. Springer-Verlag, Berlin Heidelberg New York.Google Scholar
  118. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME et al (2001): Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285:1978–1986.PubMedCrossRefGoogle Scholar
  119. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I (2002): Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 180: 396–404.PubMedCrossRefGoogle Scholar
  120. Snow V, Lascher S, Mottur-Pilson C, for the American College of Physicians —American Society of Internal Medicine (2000): Clinical guideline I. Pharmacological treatment of acute major depression and dysthymia. Ann Int Med 132: 739–742.Google Scholar
  121. Spigset O, Hagg S, Bate A (2003): Hepatic injury and pancreatitis during treatment with serotonin reuptake inhibitors: data from the World Health Organization (WHO) database of adverse drug reactions. Int Clin Psychopharmacol 18: 157–161.PubMedGoogle Scholar
  122. Sramek JJ, Zarotsky V, Cutler NR (2002): Generalized anxiety disorder: treatment options. Drugs 62: 1635–1648.PubMedCrossRefGoogle Scholar
  123. Stewart DE (2002): Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 47: 375–377.PubMedGoogle Scholar
  124. Stip E (2000): Novel antipsychotics: issues and controversies. Typicality of atypical neuroleptics. J Psychiatry Neurosci 25:137–153.PubMedGoogle Scholar
  125. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K et al (2001): Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 70: 518–524.PubMedCrossRefGoogle Scholar
  126. Swift RM (1999): Drug therapy for alcohol dependence. N Engl J Med 340: 1482–1490.PubMedCrossRefGoogle Scholar
  127. Tandon R, Jibson MD (2003): Efficacy of newer generation antipsychotics in the treatment of schizophrenia. Psychoneuroendocrinology 28: 9–26.PubMedCrossRefGoogle Scholar
  128. Taylor DM, McAskill R (2000): Atypical antipsychotics and weight gain — a systematic review. Acta Psychiatr Scand 101: 416–432.PubMedCrossRefGoogle Scholar
  129. Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000): Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35: 202–209.PubMedGoogle Scholar
  130. Thase ME (2003): Effectiveness of antidepressants: comparative remission rates. J Clin Psychiatry 64(Suppl 2): 3–7.Google Scholar
  131. Thase ME, Entsuah R, Rudolph RL (2001a): Remission rates during treatment with venlafaxine or selective reuptake inhibitors. Br J Psychiatry 178:234–241.PubMedCrossRefGoogle Scholar
  132. Thase ME, Nierenberg AA, Keller MB, Panagides J (2001b): Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients. J Clin Psychiatry 62: 782–788.PubMedCrossRefGoogle Scholar
  133. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA et al (2004): Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 184: 337–345.PubMedCrossRefGoogle Scholar
  134. Trindade E, Menon D, Topfer LA, Coloma C (1998): Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a metaanalysis. Canad Med Ass J 159:1245–1252.Google Scholar
  135. Van Walraven CMamdani MM, Wells PS, Williams JI (2001) Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Brit Med J 323:1–6.CrossRefGoogle Scholar
  136. Volovka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer JP et al (2004): Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or Haloperidol. J Clin Psychiatry 65: 57–61.CrossRefGoogle Scholar
  137. Volz HP, Gleiter CH, Möller HJ (1996): Monoaminoxidasehemmer in der Psychiatric. Nervenarzt 67: 339–347.PubMedGoogle Scholar
  138. Volz HP, Möller HJ, Reimann I, Stoll K (2000): Opipramol for the treatment of somatoform disorders. Results from a placebo-controlled trial. Eur Neuro-psychopharmacol 10: 211–217.CrossRefGoogle Scholar
  139. Von Ferber L, Lehmkuhl G, Köster I, Döpfner M, Schubert I, Frölich J, Ihle P (2003): Methylphenidatgebrauch in Deutschland. Dtsch Ärztebl 100: C38–C43.Google Scholar
  140. Walsh BT, Seidman SN, Sysko R, Gould M (2002): Placebo response in studies of major depression. Variable, substantial and growing. JAMA 287:1840–1847.PubMedCrossRefGoogle Scholar
  141. Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD (2002): Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 71:414–420.PubMedCrossRefGoogle Scholar
  142. Wetterling T (2001): Bodyweight gain with atypical antipsychotics. A comparative review. Drug Saf 24:59–73.PubMedCrossRefGoogle Scholar
  143. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Colgrove A, Boddington E (2004): Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363:1341–1345.PubMedCrossRefGoogle Scholar
  144. Williams JW Jr, Mulrow CD, Chiquette E, Hitchcock Noel P, Aguilar C, Cornell J (2000): Clinical guideline, part 2. A systematic review of newer pharmacotherapies for depression in adults: Evidence report summary. Ann Intern Med 132: 743–756.PubMedGoogle Scholar
  145. Woelk H (2000): Comparison of St John’s wort and Imipramine for treating depression: randomised controlled trial. Brit Med J 321: 536–539.PubMedCrossRefGoogle Scholar
  146. Woods JH, Winger G (1995): Current benzodiazepine issues. Psychopharmacology 118:107–115.PubMedCrossRefGoogle Scholar
  147. Yue Q-Y, Bergquist C, Gerdén B (2000): Safety of St John’s wort (Hypericum perforatum). Lancet 355: 576–577.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Martin J. Lohse
    • 1
  • Anna Lorenzen
    • 2
  • Bruno Müller-Oerlinghausen
    • 3
  1. 1.Institut für Pharmakologie und Toxikologie der Universität WürzburgWürzburg
  2. 2.Psychiatrisches Zentrum NordbadenZentrum für Psychiatrie WieslochWiesloch
  3. 3.Berlin

Personalised recommendations